[Studies on the absorption distribution and excretion of 14C-labelled sodium 7-[D(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-alpha-(4-hydroxyphenyl l) acetamido]-3-[(1-methyl-1H-tetrazol-5-yl) thiomethyl]-3-cephem-4-carboxylate (14C-cefoperazone) in rats and mice].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D002250:Carbon Radioisotopes; D002438:Cefoperazone; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism*; D005243:Feces / Q000032:analysis; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008431:Maternal-Fetal Exchange; D051379:Mice; D011247:Pregnancy; D011485:Protein Binding; D051381:Rats; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D002250:Carbon Radioisotopes; D002511:Cephalosporins; D002438:Cefoperazone